Repatha Cost in Vermont 2026: Price, Insurance, Medicaid, and Compounded Evolocumab

Evolocumab is the generic name for Repatha, a human monoclonal antibody that inhibits PCSK9 and is given by subcutaneous injection. It is FDA-approved to lower LDL cholesterol and, in adults at increased cardiovascular risk, to reduce major adverse cardiovascular events. It is not related to the GLP-1 class of weight-management or diabetes drugs, and it should not be confused with a compounded or peptide product marketed under a similar name.

Repatha does not have one Vermont price. What a specific patient pays depends on which of several separate pathways applies to that prescription: manufacturer cash pay, a manufacturer copay card (commercial insurance only), a government payer's formulary and prior-authorization rules, or a needs-based assistance program. These pathways are not interchangeable, and a number quoted for one does not apply to another.

The Short Answer

As of late 2025 and into 2026, Amgen's direct-to-patient AmgenNow program advertises a cash price of $239 per month for patients with a valid Repatha prescription, including people who are uninsured, on a high-deductible plan, or paying out of pocket by choice. Separately, Amgen's current copay-card program advertises as little as $25 for a one-month supply or $50 for a three-month supply for eligible commercially insured patients; that card explicitly excludes anyone whose prescription is paid in whole or in part by Medicare, Medicaid, TRICARE, or another government program. Neither figure predicts what a Vermont Medicaid or Medicare Part D member will pay, because that number comes from the plan's formulary tier, prior-authorization outcome, and benefit design, not from a manufacturer program. Prices, program terms, and eligibility rules are set by Amgen and by federal and state payers and can change; verify the current terms before a patient relies on any dollar figure in this article.

Four Payment Pathways, Not One Price

1. Commercial insurance plus the manufacturer copay card. Amgen's enrollment page states the current copay-card terms, described above, for eligible commercially insured patients. Eligibility and maximum benefit limits apply, and the card is not a cash-pay substitute.
2. AmgenNow cash pay. Amgen's announcement describes a $239 monthly direct-to-patient price for patients with a valid prescription. This is a national program; the price is not Vermont-specific.
3. A government plan (Medicaid, Medicare, TRICARE, VA). Cost is set by that program's formulary, utilization management, pharmacy network, and the specific claim, not by either manufacturer program above.
4. Patient assistance. Amgen's Safety Net Foundation may provide Repatha at no cost to people who meet current residency, income, and insurance criteria. Amgen's cost page routes patients to this application-based option; it is not automatic.

Paying cash through AmgenNow generally means the fill is not processed as an insurance claim, which can affect whether the payment counts toward a deductible or out-of-pocket maximum. Ask the plan and the dispensing pharmacy before choosing that route.

Vermont Medicaid: Check the Current List, Not a Summary

No general article can promise that a specific Vermont Medicaid member has Repatha coverage, a particular copay, or particular prior-authorization criteria, because drug-list status and clinical criteria change and a listed drug can still carry diagnosis, age, quantity, prescriber, or documentation conditions.

The Department of Vermont Health Access (DVHA) maintains the authoritative source: its Preferred Drug List and clinical-criteria page. The pharmacy provider manual explains that drugs requiring prior authorization are identified there, that PA requests go through the provider portal or the pharmacy benefit manager, and that a 72-hour emergency-fill process exists when its conditions are met.

Before assuming approval or denial, confirm with the plan or pharmacy:

• whether Repatha is preferred, nonpreferred, or excluded on the member's current benefit;
• whether a different agent must be tried or documented first;
• the LDL-C and diagnosis documentation the plan currently requires;
• quantity limits and which presentation (dose, device) can be billed;
• the permitted pharmacy network; and
• the member's actual copay after an approved claim.

A rejected claim is not proof of an ineligible drug. It can mean a missing PA, a mismatched product or quantity, a prescriber enrollment issue, or an out-of-network pharmacy. One documented Vermont-specific change: DVHA announced that, effective January 13, 2023, Repatha no longer required an accredited specialty pharmacy and could be filled at any Vermont Medicaid-enrolled pharmacy (DVHA notice). Because rules can change again, confirm the current claim before transferring a prescription.

Building a Prior-Authorization File

Insurers do not all use identical criteria, but a defensible PA submission typically connects the patient's history to the FDA-approved indication and the plan's own policy. It commonly includes a recent lipid panel and prior values, the relevant cardiovascular-risk or hypercholesterolemia diagnosis, prior lipid-lowering therapies with doses, dates, and response or documented intolerance, the requested Repatha dose and device, and the plan's completed form with matching clinical notes.

Cardiology guideline bodies (the American Heart Association and American College of Cardiology) have published joint guidance on cholesterol management and separate expert consensus guidance on when nonstatin therapies, including PCSK9 antibodies, may be considered for patients with atherosclerotic cardiovascular disease. These are clinical guidance documents for prescribers, not insurer contracts, and a given plan's PA criteria can be stricter or use different thresholds. A clinician's office preparing a Vermont PA request should confirm current guideline language directly from the issuing societies rather than from a secondhand summary, since guideline documents are periodically updated.

Published research on PCSK9-inhibitor access (the class that includes evolocumab) has previously found that a meaningful share of prescriptions abandoned after a coverage denial or a high copay, particularly in the years shortly after these drugs launched. That literature is several years old, reflects an earlier reimbursement landscape, and should not be assumed to describe 2026 Vermont approval rates. The practical takeaway that has not changed is that prior authorization is a real access barrier, not a formality, and cost should be confirmed before assuming a prescription will be dispensed.

Medicare Part D in Vermont

CMS's final CY2026 Part D redesign materials set the 2026 annual out-of-pocket threshold at $2,100 for covered Part D drugs, up from the 2025 threshold, under the inflation-indexing built into the redesigned benefit (CMS fact sheet). After a Part D enrollee's qualifying spending reaches that threshold, the enrollee owes no further cost sharing for covered Part D drugs for the remainder of the plan year.

That threshold does not tell a patient whether Repatha is on a given plan's formulary. Before relying on it, confirm:

• whether Repatha appears on the plan's 2026 formulary and at what tier;
• whether PA, step therapy, or a quantity limit applies;
• the preferred pharmacy and allowed supply length;
• the expected cost at each benefit phase; and
• whether an AmgenNow cash purchase would count toward Part D spending (it should not be assumed to).

Vermonters enrolled in Medicare drug coverage may also qualify for VPharm, the state's pharmaceutical assistance program, which can help with eligible Medicare prescription costs and, at some program levels, Part D premiums. Eligibility and covered costs are tier-specific (DVHA program summary). Have the pharmacy bill Part D first and VPharm second, per current DVHA instructions.

Commercial Insurance: No Single Answer Across Vermont Plans

Commercial coverage varies by employer, carrier, pharmacy benefit manager, and plan year. Plans issued by the same carrier can use different formularies, so it is not accurate to state that Repatha is covered the same way on every Blue Cross Blue Shield of Vermont, MVP, marketplace, or self-funded employer plan.

The current Repatha copay-card enrollment page is the only reliable source for the live dollar amounts and eligibility rules; use its current output rather than a number copied from an older article. Ask whether manufacturer copay assistance counts toward the plan's deductible or out-of-pocket maximum, since accumulator and maximizer rules vary by plan and can change the real benefit of the card.

A practical sequence:

1. Have the pharmacy run the claim and report the exact reject message or copay.
2. If PA is required, have the prescriber submit the plan's current form with claim-matched documentation.
3. If approved but still unaffordable, compare the commercial copay card against the plan price.
4. If uninsured or choosing cash, compare AmgenNow's $239 option against Safety Net Foundation eligibility.
5. Confirm before paying whether the chosen route counts toward insurance accumulators.

Compounded Evolocumab Is Not a Routine Lower-Cost Substitute

Evolocumab is a licensed biological product, not a small-molecule drug. FDA's compounding Q&A states directly that biological products are not eligible for the compounding exemptions under sections 503A or 503B, and that federal law does not provide a pathway to market a biologic prepared outside an approved biologics license application (FDA compounding Q&A).

This is a materially different situation from a pharmacy compounding a conventional small-molecule medication for an individual patient. FDA does have separate, narrow guidance covering limited handling of certain biological products, such as repackaging, but none of that creates an interchangeable, pharmacy-made evolocumab product or supports a marketing claim of a free or near-free "compounded" substitute.

Anyone offered "compounded evolocumab" in Vermont should ask for the product's FDA biologics license, the manufacturer, the National Drug Code, and the dispensing source before assuming it is equivalent to Repatha. If those cannot be produced, the product should not be treated as a lower-cost legal alternative.

What the Cost Is Paying For: Clinical Evidence, Described Cautiously

Repatha's evidence base includes large randomized cardiovascular-outcomes trials, though the specific numeric results below should be verified against the original publications before being used in patient-facing or clinical material; the identifiers previously associated with this claim in an earlier draft could not be confirmed and have been removed rather than repeated.

• FOURIER, a large randomized trial in patients with established atherosclerotic cardiovascular disease already on statin therapy, found that adding evolocumab produced a substantial additional reduction in LDL-C and a statistically significant reduction in a composite cardiovascular outcome over roughly two years of follow-up, with a modest absolute risk difference.
• A more recently reported trial (publicly described as VESALIUS-CV) extended outcome evidence to patients with atherosclerosis or diabetes but no prior heart attack or stroke, reporting a reduced rate of major cardiovascular events over several years of follow-up compared with placebo.
• RUTHERFORD-2, a trial in patients with heterozygous familial hypercholesterolemia, reported large placebo-corrected LDL-C reductions with both approved dosing schedules.
• GLAGOV, an intravascular-ultrasound imaging trial in statin-treated coronary disease patients, reported plaque regression with evolocumab versus progression with placebo; this is an imaging surrogate outcome, not a mortality or hard-event result, and should not be described as one.

FDA broadened Repatha's cardiovascular-risk indication in August 2025 to include reducing major adverse cardiovascular events in adults at increased risk, without requiring a prior heart attack or stroke (Amgen's announcement of the label update). An expanded FDA indication does not automatically mean a payer will cover the drug for that broader population; coverage still depends on the member's plan and documentation.

Evidence boundary: it is established that evolocumab lowers LDL-C substantially and that trial evidence supports a reduction in cardiovascular events in at-risk statin-treated populations studied to date. It is not established that every patient with an elevated LDL-C receives the same absolute benefit, and coverage determinations are a separate, payer-specific question from clinical efficacy. Treatment decisions belong to a licensed clinician weighing the patient's individual risk, prior therapy, and preferences.

Dosing, Devices, and Storage

Labeled adult dosing is 140 mg every two weeks or 420 mg once monthly by subcutaneous injection; the monthly dose can be given as three consecutive 140 mg injections within 30 minutes (DailyMed label). This article does not provide individualized dosing guidance; the prescribing clinician determines the regimen for a given patient.

Amgen discontinued the Pushtronex 420 mg on-body infusor effective June 30, 2024, and has transitioned presentations, including newer latex-free options (manufacturer device FAQ; current injection-support page). Because older labels or pharmacy records can still list discontinued NDCs, patients with a device preference or latex sensitivity should have the pharmacy confirm the current product rather than relying on the word "pen" or "syringe" alone.

The label permits refrigerated storage at 36°F to 46°F (2°C to 8°C), protected from light, or room-temperature storage at 68°F to 77°F (20°C to 25°C) in the original carton for up to 30 days. Do not freeze the product or expose it above 77°F. Follow the current label's exact time and temperature limits rather than an informal rule of thumb.

Telehealth Prescribing in Vermont

A telehealth visit does not create a separate or cheaper Repatha product. A clinician treating a patient physically located in Vermont must hold an appropriate current Vermont credential; pandemic-era temporary registrations have expired (Vermont Board of Medical Practice licensing routes). The Board's telemedicine prescribing policy states that a questionnaire alone is not an adequate initial evaluation and that telemedicine prescribing carries the same professional accountability as in-person prescribing, including a documented diagnosis and an ongoing medical record.

Whether telehealth is adequate for a given patient depends on the clinical evaluation, available records and lab results, and the payer's own rules; telehealth initiation does not by itself improve the odds of prior-authorization approval. A legitimate telehealth prescriber should be able to state the Vermont license used, where labs and follow-up care will occur, and should send the same documentation an in-person prescriber's office would send to a plan.

Verification Checklist: What Is Stable vs. What Must Be Checked at the Time of Use

Some facts about Repatha are set at the federal regulatory or major-trial level and change rarely. Others (price, formulary tier, PA criteria, copay-card terms) are controlled by insurers, the state Medicaid agency, or the manufacturer's own program pages and can change without notice. Confusing the two categories is the most common way patients and staff get an outdated answer. Use this checklist to separate them before quoting a number to a patient.

Stable facts (re-verify only if the label or guideline changes; check annually at most)

• FDA-approved indication and dosing regimen: confirm against the current DailyMed label, not a memory of an older label.
• Compounding status: biologics, including evolocumab, are not eligible for 503A/503B exemptions per FDA's compounding Q&A; this is a standing federal position, not a state-by-state rule.
• Device history: Pushtronex was discontinued June 30, 2024; this is a completed, dated fact, not something that will revert.
• General cardiovascular trial evidence base (FOURIER, RUTHERFORD-2, GLAGOV, and newer outcome trials): the qualitative direction of findings is stable; do not treat this article's descriptions as a substitute for the peer-reviewed publications.

Volatile facts (verify at the moment of the patient's fill; do not carry forward from a prior visit or prior year)

• The AmgenNow cash price and eligibility rules (confirm on Amgen's current program page).
• The commercial copay-card dollar amount and exclusions (confirm on Amgen's current enrollment page).
• Vermont Medicaid formulary tier, PA criteria, and quantity limits for the specific member (confirm on DVHA's current Preferred Drug List page and the member's live claim).
• Whether a specific commercial plan or Medicare Part D plan covers Repatha in 2026, and at what tier (confirm on that plan's current formulary, not a prior year's).
• VPharm eligibility and benefit level for a specific Medicare enrollee (confirm with DVHA).
• Whether a cash or copay-card payment counts toward a deductible or out-of-pocket maximum (confirm with the specific plan).

If a staff member cannot answer an item in the second list from a source dated within the current plan year, treat the number as unverified rather than repeating a figure from an earlier conversation or an older printout.

A Price-Check Script

Ask the same questions of the insurer, the pharmacy, and manufacturer support so the answers are comparable:

• "Is Repatha covered on my exact 2026 benefit, and which NDC or device is preferred?"
• "Does it require prior authorization, step therapy, or a quantity limit?"
• "What is my cost for a 28-day supply and for an 84-day supply at this pharmacy?"
• "Is a different in-network pharmacy less expensive?"
• "If I pay $239 through AmgenNow, will that spending count toward my deductible or out-of-pocket maximum?"
• "If I use the commercial copay card, how will the payment be treated by my plan?"
• "If I have Medicare and VPharm, did the pharmacy bill both in the correct order?"
• "If the claim was rejected, what is the exact code, and what must the prescriber submit?"

Record the representative's name, date, reference number, quoted supply length, and product identifier so a one-month insurance quote is not compared against a three-month card quote, or a discontinued device against the current autoinjector.